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Abstract
There are currently 13 indications approved by the U.S. Food and Drug Administration for use of hyperbaric oxygen therapy. The European
Consensus Conference on Hyperbaric Medicine has 28 indications approved for its use. However, neither includes the use of hyperbaric
oxygen therapy for neurological conditions such as migraines with aura. Recent research has made the attempt to fully understand the use
of hyperbaric therapy in treatment of neurological conditions, but results have so far been inconclusive. We report a 23-year-old female with
an 11-year history of migraines with aura who has received inadequate pharmacological treatment for her migraines since she began having
them. Migraines have led her to significant loss of function. The patient underwent treatment at 1.5 absolute atmospheres in a hyperbaric
chamber Monday through Friday for 1 hour each day for a total of 40 sessions but reported missing a few sessions over the 8-week period.
No more than 1 session during a given week was missed and the patient received no other treatments for her migraines throughout this time
period. By her 24th treatment, the patient had only experienced a single migraine with aura but without debilitating pain. The patient stated
she had never had a migraine with such little intensity prior to initiation of hyperbaric treatment and did not have to take any days off from
work or school. Follow-up at the end of her 40-day treatment period revealed a highly-satisfied patient who had only experienced the single
episode of a mild migraine during the entire course of treatment. Thus, we believe that further research needs to be done to realize the full
potential of hyperbaric oxygen therapy in the treatment of neurological conditions as this case highlights the potential for using hyperbaric
oxygen therapy as prophylaxis against attacks in patients with treatment resistant migraines with aura.
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INTRODUCTION

The use of hyperbaric oxygen therapy (HBO) has been a
widely-accepted form of treatment for certain conditions.
Hyperbaric oxygen therapy involves the inhalation of 100%
oxygen in a hyperbaric chamber at a pressure higher than 1
atm or 760 mmHg. The beneficial effects of HBO results from
generating physiologic hyperoxia in tissue by fully saturating
hemoglobin molecules and increasing the amount of oxygen
dissolved in the plasma. This allows tissue to meet its oxygen
demand through the dissolved oxygen alone without the need
to utilize the oxygen linked to hemoglobin.1-5 As a class II
medical device, hyperbaric chambers are currently approved
for 13 indications by the U.S. Food and Drug Administration
(FDA) and Hyperbaric Medical Society.6,7 Indications currently
include adjuvant therapy in wound ischemia, thermal burn
treatment, blood loss anemia, air embolisms, carbon monoxide
poisoning, clostridial myonecrosis, crush injury, decompression sickness, chronic refractory osteomyelitis, necrotizing
soft-tissue infections, radiation tissue injury, ischemic skin
grafts and flaps, and intracranial abscess (Table 1), but does
not include neurologic conditions.5,8-10 The 2016 European
Consensus Conference on Hyperbaric Medicine resulted in a
list of 9 indications for HBO to be used as a primary therapy,
with an additional 13 indications where there is acceptable
evidence that HBO may be used as treatment, as well as 6 indi238

cations where HBO may be considered as an optional modality.
Amongst the 13 FDA-approved indications and the 28 indications that resulted from the 2016 European Consensus Conference on Hyperbaric Medicine, neither group includes treatment
for neurological conditions such as migraines with aura.5,8,9,11
Current treatments for migraines and other headaches are
based around relieving the symptoms through the reduction of
cerebral blood flow.12 HBO substantially increases the amount
of arterial oxygen and therefore effectively achieves cerebral
vasoconstriction, thus treating the migraine.1,13 Based on this
case report, we believe the current approved indications for
HBO need to be expanded to include resistant migraines after
further randomized control trials demonstrate efficacy in a
larger patient population (Table 1).

CASE HISTORY

We present a 23-year-old female with a self-reported history
of migraines with aura since the age of 12 with no other relevant medical history. She described her migraines as severe
in nature lasting 4–6 hours, 3 times monthly on average. Her
extreme pain and sensitivity to light and sound often impaired
daily function, causing a loss of vision and inability to focus
on tasks at hand. The patient also reported frequent abdominal
pain leading to emesis during her migraine attacks. Overall,
the migraines hindered her functional status as she had missed
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Table 1: Current U.S. Food and Drug Administration
approved indications and recommended update to the
current indications for hyperbaric oxygen therapy6,7
No.

Indications

Current U.S. Food and Drug
Administration approved
indications
1
2
3
4
5
6
7
8
9
10
11
12
13
Recommended update to the
current indications
14
15
16

Gas embolism
Carbon monoxide poisoning
Gas gangrene
Crush injury/compartment
syndrome
Decompression sickness
Healing of complicated wounds
Blood loss anemia
Intracranial abscess
Necrotizing fasciitis
Refractory osteomyelitis
Delayed radiation soft tissue injury
Compromised skin grafts
Thermal burns

Migraines
Stroke
Other neurological conditions

many days of school and work due to her condition. She had
been managed by her primary care physician since the onset
of her migraines at an early age; however, she experienced
migraines refractory to Imitrix and adjustments to birth control.
The patient would typically get mild relief using Excedrin,
caffeine consumption, removal of light, and use of ice packs.
Evaluation of this patient prior to initiation of treatment revealed no contraindications to HBO. The patient underwent
treatment at 1.5 absolute atmospheres in a hyperbaric chamber
Monday through Friday for 1 hour each day, for a total of 40
sessions, but reported missing a few sessions over the 8-week
period. No more than one session during a given week was
missed and the patient received no other treatments for her
migraines throughout this time period. By her 24th treatment,
the patient had only experienced a single migraine with aura
but without debilitating pain. The patient stated she has never
had a migraine with such little intensity prior to initiation of
hyperbaric treatment and did not have to take any days off from
work or school during treatment. Follow-up at the end of her
40-day treatment period revealed a highly-satisfied patient who
had only experienced the single episode of a mild migraine
during the entire course of treatment. It is important to indicate
that the patient did not receive any additional therapy during
HBO treatments.

DISCUSSION

The most recent guidelines for management of acute migraine
attacks involve use of triptans, non-steroidal anti-inflammatory
drugs and antiemetics. Prophylactic treatment often includes
the use of beta blockers, tricyclic antidepressants, and antiMedical Gas Research ¦ December ¦ Volume 9 ¦ Issue 4
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convulsants. Response to such therapies is highly variable and
is often effective only in a select group of patients. They are
often prescribed based upon the patient’s tolerability of the
medication and comorbid conditions. Migraine attacks with
aura are often less responsive to triptans and carry an even
more differentiated response when compared to a migraine
without aura.12,14 Thus, a great need for alternative treatments
for migraines exists, especially for patients whose migraines
are refractory to current pharmacologic therapies.
As illustrated by this report, HBO may provide a novel approach in reducing the disability of the migraineur by providing
relief, and by reducing the frequency of attacks refractory to
pharmacologic therapy. While the exact inflammatory mediators responsible for migraine headaches are still unknown, it
is known that inflammation plays a role in the activation of
the trigeminovascular system leading to migraines with the
characteristic throbbing pain.13,15,16 The peripheral activation
of the trigeminovascular nociceptors in the dura mater leads
the release of vasoactive dilators including calcitonin generelated peptide causing long lasting stimulation and vasodilation.16-18 The beneficial effects of HBO are caused through
the physiologic consequences of 100% inspired oxygen and
exposure to elevated atmospheric pressures. This leads to
higher levels of dissolved oxygen in plasma and subsequent
arterial constriction in the brain, thus aborting and preventing
the migraine.1-4,15,19
The current understanding of the pathophysiology behind
migraines with aura combined with the increasing evidence
supporting the anti-inflammatory and anti-vasodilatory effects
of HBO, suggests that our patients’ relief could be related to
HBO decreasing the inflammatory response that leads to the
activation of the trigeminovascular pathway.10,13,15,20 A study
by Myers et al.21 demonstrated a significant reduction (P <
0.05) in migraine relief in patients undergoing HBO versus
those who underwent normobaric oxygen therapy. Wilson et
al.15 showed a significant decrease in subjective pain in those
who underwent HBO versus the control group of females with
migraine with aura. Other studies by Eftedal et al.1,22,23 showed
insignificant prophylactic measure against migraines with the
use of HBO. It is important to note that these studies have
limited sample sizes. A Cochrane review on the usage of HBO
to prevent migraines showed no evidence to suggest that HBO
could prevent migraine attacks, reduce the incidence of nausea
and vomiting, or reduce the requirement for rescue medication
based upon 11 trials.23 On the contrary, we present a patient
who had a reduction in frequency, intensity, symptomatology,
and need for rescue medications after HBO treatment. To
truly judge the efficacy of HBO and take to into account the
inherent variability in response to different treatments, larger
studies are needed. Our case of this 23-year-old female who
experienced a reduction in the frequency and intensity of her
migraines after HBO provides the evidence for the use of
HBO in the management of chronic migraine. Of note, there
has been a limited follow up time with the patient so we are
unable to determine how long this treatment modality will
remain effective in the long term. The purpose of this article
is to expand the currently FDA-approved indications for HBO,
such as migraine, headaches based on randomized controlled
239

[Downloaded free from http://www.medgasres.com on Monday, February 3, 2020, IP: 205.142.7.7]

Matera et al. / Med Gas Res

studies addressing long lasting efficacy in large patient populations. While there has been progress both in the understanding
of migraine pathophysiology and the mechanism of action of
HBO over the past few years, further research is needed to
expand our knowledge and create better treatments for patients
with migraines.
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